<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Formosa Pharmaceuticals, Inc. — News on 6ix</title>
<link>https://6ix.com/company/formosa-pharmaceuticals-inc</link>
<description>Latest news and press releases for Formosa Pharmaceuticals, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 06:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/formosa-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<item>
<title>Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases</title>
<link>https://6ix.com/company/formosa-pharmaceuticals-inc/news/formosa-pharmaceuticals-and-singapore-eye-research-institute-seri-partner-to-advance-novel-ophthalmic-formulations-for-corneal-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/formosa-pharmaceuticals-inc/news/formosa-pharmaceuticals-and-singapore-eye-research-institute-seri-partner-to-advance-novel-ophthalmic-formulations-for-corneal-diseases</guid>
<pubDate>Thu, 30 Apr 2026 06:30:00 GMT</pubDate>
<description>Formosa Pharmaceuticals, Inc. ("Formosa", 6838.TW) and the Singapore Eye Research Institute ("SERI") are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa's proprietary APNT® (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI's world-class clinical research expertise, led by renowned Clinician Scientist, Associate Professor Yu-Chi Liu, MD, PhD.</description>
</item>
<item>
<title>Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery</title>
<link>https://6ix.com/company/formosa-pharmaceuticals-inc/news/formosa-pharmaceuticals-announces-licensing-agreement-with-arrotex-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery-1</link>
<guid isPermaLink="true">https://6ix.com/company/formosa-pharmaceuticals-inc/news/formosa-pharmaceuticals-announces-licensing-agreement-with-arrotex-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery-1</guid>
<pubDate>Mon, 23 Feb 2026 06:00:00 GMT</pubDate>
<description>Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Arrotex Pharmaceuticals Pty Ltd. ("Arrotex"), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), an innovative topical eyedrop for the treatment of inflammation and pain following ocular surgery in Australia and New Zealand. Arrotex, 'Australia's Medicines Company', currently fulfills 50% of</description>
</item>
<item>
<title>Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery</title>
<link>https://6ix.com/company/formosa-pharmaceuticals-inc/news/formosa-pharmaceuticals-announces-licensing-agreement-080000195</link>
<guid isPermaLink="true">https://6ix.com/company/formosa-pharmaceuticals-inc/news/formosa-pharmaceuticals-announces-licensing-agreement-080000195</guid>
<pubDate>Mon, 12 Jan 2026 08:00:00 GMT</pubDate>
<description>Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil Pharmaceuticals, Co., Ltd ("Samil", 000520.KS), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery in South Korea. Samil, established in 1947, is one of the most prominent Korean manufactu</description>
</item>
<item>
<title>Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery</title>
<link>https://6ix.com/company/formosa-pharmaceuticals-inc/news/formosa-pharmaceuticals-announces-licensing-agreement-100000434</link>
<guid isPermaLink="true">https://6ix.com/company/formosa-pharmaceuticals-inc/news/formosa-pharmaceuticals-announces-licensing-agreement-100000434</guid>
<pubDate>Wed, 03 Dec 2025 10:00:00 GMT</pubDate>
<description>Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Rxilient Medical Pte. Ltd. ("Rxilient"), for exclusive rights to the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine currently indicated for the treatment of inflammation and pain following ocular surgery in key ASEAN regions, including Indonesia, Philippines, Singapore, and Thailand. R</description>
</item>
<item>
<title>Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals</title>
<link>https://6ix.com/company/formosa-pharmaceuticals-inc/news/harrow-acquires-us-commercial-rights-to-byqlovitm-clobetasol-propionate-ophthalmic-suspension-005percent-from-formosa-pharmaceuticals</link>
<guid isPermaLink="true">https://6ix.com/company/formosa-pharmaceuticals-inc/news/harrow-acquires-us-commercial-rights-to-byqlovitm-clobetasol-propionate-ophthalmic-suspension-005percent-from-formosa-pharmaceuticals</guid>
<pubDate>Mon, 09 Jun 2025 11:00:00 GMT</pubDate>
<description>NASHVILLE, Tenn. & TAIPEI, Taiwan, June 09, 2025--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain fo</description>
</item>
</channel>
</rss>